HPA001591

antibody from Atlas Antibodies

Targeting: RBM39 CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RNPC2

Western blot (Enhanced validation)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA001591

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA001591, RRID:AB_1079749

Product name

Anti-RBM39

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human RBM39, Gene description: RNA binding motif protein 39, Alternative Gene Names: CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RNPC2, Validated applications: WB, IHC, Uniprot ID: Q14498, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.1 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency

Kohsaka S, Yagishita S, Shirai Y, Matsuno Y, Ueno T, Kojima S, Ikeuchi H, Ikegami M, Kitada R, Yoshioka K, Toshimitsu K, Tabata K, Yokoi A, Doi T, Yamamoto N, Owa T, Hamada A, Mano H
npj Precision Oncology 2024;8(1)

---

Targeted protein degradation via intramolecular bivalent glues

Hsia O, Hinterndorfer M, Cowan A, Iso K, Ishida T, Sundaramoorthy R, Nakasone M, Imrichova H, Schätz C, Rukavina A, Husnjak K, Wegner M, Correa-Sáez A, Craigon C, Casement R, Maniaci C, Testa A, Kaulich M, Dikic I, Winter G, Ciulli A
Nature 2024;627(8002):204-211

---

Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins

Hsieh M, Wei Y, Li L, Nguyen L, Lin Y, Yong J, Sun X, Wang X, Luo X, Knutson S, Bracken C, Daley G, Powers J, Zhu H
Journal of Clinical Investigation 2024;134(15)

---

Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation

Coomar S, Mota P, Penson A, Schwaller J, Abdel-Wahab O, Gillingham D
Molecular Cancer Research 2023;21(8):768-778

---

Arginine reprograms metabolism in liver cancer via RBM39

Mossmann D, Müller C, Park S, Ryback B, Colombi M, Ritter N, Weißenberger D, Dazert E, Coto-Llerena M, Nuciforo S, Blukacz L, Ercan C, Jimenez V, Piscuoglio S, Bosch F, Terracciano L, Sauer U, Heim M, Hall M
Cell 2023;186(23):5068-5083.e23

---

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

Campagne S, Jutzi D, Malard F, Matoga M, Romane K, Feldmuller M, Colombo M, Ruepp M, Allain F
Nature Communications 2023;14(1)

---

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero-Sánchez A, Morris B, Roosen M, Wardak L, De Conti G, Velds A, Lieftink C, Thijssen B, Beijersbergen R, Bernards R, Leite de Oliveira R
Life Science Alliance 2022;5(9):e202101348

---

A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues

Yamanaka S, Horiuchi Y, Matsuoka S, Kido K, Nishino K, Maeno M, Shibata N, Kosako H, Sawasaki T
Nature Communications 2022;13(1)

---

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, Poon E, Eckold C, Valbuena G, Xu Y, Liu Y, da Costa B, Gruet M, Wickremesinghe C, Benito A, Kramer H, Montoya A, Carling D, Want E, Jamin Y, Chesler L, Keun H
Nature Communications 2022;13(1)

---

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

Lu S, De Neef E, Thomas J, Sabio E, Rousseau B, Gigoux M, Knorr D, Greenbaum B, Elhanati Y, Hogg S, Chow A, Ghosh A, Xie A, Zamarin D, Cui D, Erickson C, Singer M, Cho H, Wang E, Lu B, Durham B, Shah H, Chowell D, Gabel A, Shen Y, Liu J, Jin J, Rhodes M, Taylor R, Molina H, Wolchok J, Merghoub T, Diaz L, Abdel-Wahab O, Bradley R
Cell 2021;184(15):4032-4047.e31

---

The Influenza A Virus Endoribonuclease PA-X Usurps Host mRNA Processing Machinery to Limit Host Gene Expression

Gaucherand L, Porter B, Levene R, Price E, Schmaling S, Rycroft C, Kevorkian Y, McCormick C, Khaperskyy D, Gaglia M
Cell Reports 2019;27(3):776-792.e7

---

UBE2G1 governs the destruction of cereblon neomorphic substrates

Lu G, Weng S, Matyskiela M, Zheng X, Fang W, Wood S, Surka C, Mizukoshi R, Lu C, Mendy D, Jang I, Wang K, Marella M, Couto S, Cathers B, Carmichael J, Chamberlain P, Rolfe M
eLife 2018;7

---

Negative autoregulation of BMP dependent transcription by SIN3B splicing reveals a role for RBM39

Faherty N, Benson M, Sharma E, Lee A, Howarth A, Lockstone H, Ebner D, Bhattacharya S
Scientific Reports 2016;6(1)

---

CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression

Sillars-Hardebol A, Carvalho B, Beliën J, de Wit M, Delis-van Diemen P, Tijssen M, van de Wiel M, Pontén F, Meijer G, Fijneman R
Cellular Oncology 2012;35(4):293-300

Western blot

Enhanced validation

Submitted by

Atlas Antibodies (provider)

Enhanced method

Genetic validation

Main image

Experimental details

Western blot analysis in Caco-2 cells transfected with control siRNA, target specific siRNA probe #1, using Anti-RBM39 antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.

Sample type

Human

Protocol

Protocol